Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age-Reference-Cited by-同舟云学术

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age

Published:2020-06-02 Issue:6 Volume:16 Page:1280-1291
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Vesikari Timo¹,Peyrani Paula²,Webber Chris³,Van Der Wielen Marie⁴,Cheuvart Brigitte⁴,De Schrevel Nathalie⁵,Aris Emmanuel⁴,Cutler Mark⁶,Li Ping²,Perez John L.²

Affiliation:

1. Nordic Research Network Ltd, Tampere, Finland

2. Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Collegeville, PA, USA

3. Pfizer Vaccine Clinical Research and Development, Pfizer Ltd, Hurley, Berkshire, UK

4. Global Vaccines Research and Development, GlaxoSmithKline, Wavre, Belgium

5. Global Vaccines Research and Development, GlaxoSmithKline, Rixensart, Belgium

6. Pfizer Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA

Funder

Pfizer

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1746110

Reference26 articles.

1. Centers for Disease Control and Prevention. Chapter 14: meningococcal disease. Public Health Foundation. [accessed 2019 June 3] https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/mening.pdf.

2. European Centre for Disease Prevention and Control. Surveillance Atlas of infectious diseases. [accessed 2019 June 3]. https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases.

3. Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination;Expert Review of Vaccines;2024-06-07

2. The important lessons lurking in the history of meningococcal epidemiology;Expert Review of Vaccines;2024-04-04

3. Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?;Vaccines;2023-05-04

4. A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12–14-month-old children;Vaccine;2023-01

5. Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting;Current Pain and Headache Reports;2022-11-23